Serious pregnancy condition drug developer nabs CHF60m VC-backed Series B

Swiss biopharmaceutical company ObsEva, which develops drugs focusing on serious conditions compromising pregnancy, has raised a CHF60m ($59m) Series B round from a string of venture capital firms.